基于MRI的质子密度脂肪分数联合脂肪组织识别代谢功能障碍相关脂肪性肝炎
该回顾性研究纳入197例接受肝活检、MRI-PDFF和瞬时弹性成像的MASLD患者,构建联合PDFF与总脂肪组织指数的MR-PAT模型识别MASH。模型AUC为0.866,Bootstrap内部验证AUC为0.870,诊断性能显著优于现有无创检测(均P<0.05)。
要点
- MR-PAT模型联合PDFF与TATI,可无创识别MASH,AUC达0.866。
- 模型性能在临床相关亚组中保持一致,且优于现有无创检测。
- PDFF与TATI均为MASH的独立危险因素。
核心结论
- 联合MRI-PDFF与TATI的MR-PAT模型可准确、稳健地无创识别MASH,性能优于现有无创检测,有望用于MASLD风险分层。
研究设计与样本
- 回顾性纳入197例连续MASLD患者,均接受肝活检、MRI-PDFF和瞬时弹性成像。
- 采用单因素及多因素logistic回归筛选MASH独立预测因子并构建联合模型。
- 通过1000次Bootstrap重采样进行内部验证,并与现有无创检测比较诊断性能。
诊断标准与关键数值
- MR-PAT模型识别MASH的AUC为0.866,Bootstrap内部验证AUC为0.870。
- 多因素分析显示PDFF和TATI为MASH的独立危险因素。
- MR-PAT模型诊断性能显著优于所有现有无创检测(均P<0.05)。
临床应用与阅片要点
- 在MASLD患者中可联合测量MRI-PDFF与总脂肪组织指数,用于无创识别MASH并辅助风险分层。
- 模型性能在临床相关亚组中一致,但应用时仍需结合肝活检参考标准背景。
局限性
- 研究为回顾性设计,且仅进行内部Bootstrap验证,未提及外部验证。
英文原文(摘要)· 点击展开
Insights Imaging. 2026 Oct 29;17(1):268. doi: 10.1186/s13244-026-02444-9. ABSTRACT OBJECTIVES: To develop a non-invasive diagnostic model combining magnetic resonance imaging (MRI)-derived proton density fat fraction (PDFF) and adipose tissue for identifying metabolic dysfunction-associated steatohepatitis (MASH). MATERIALS AND METHODS: A total of 197 consecutive patients with metabolic dysfunction-associated steatotic liver disease (MASLD) who underwent liver biopsy, MRI-PDFF, and transient elastography (TE) were retrospectively enrolled. Independent predictors of MASH were identified using univariate and multivariate logistic regression analyses. A combined model was constructed and internally validated via 1000 bootstrap resamples. The diagnostic performance was compared with that of established non-invasive tests (NITs). RESULTS: Multivariable logistic regression analyses demonstrated that the PDFF and total adipose tissue index (TATI) were independent risk factors for MASH. The MRI-based PDFF-adipose tissue (MR-PAT) model achieved an area under the receiver operating characteristic curve (AUC) of 0.866 for MASH identification. Bootstrap internal validation yielded an AUC of 0.870. The performance of the models was consistent across clinically relevant subgroups. The diagnostic performance of the MR-PAT model for MASH identification was significantly better than that of all the established NITs (all p < 0.05). CONCLUSION: The MR-PAT model, combining MRI-derived PDFF and TATI, provides an accurate and robust non-invasive tool for identifying MASH. It outperforms widely recognized NITs and holds promise for risk stratification in patients with MASLD. KEY POINTS: Question MASH is a critical histological endpoint of MASLD, but reliable non-invasive tools for its assessment remain inadequate. Findings The MR-PAT model integrating MRI-based PDFF and adipose tissue quantification demonstrates robust and excellent diagnostic performance for identifying MASH. Critical Relevance Statement The MR-PAT model leverages hepatic steatosis and the adipose tissue burden to elucidate the pathophysiological mechanisms driving steatohepatitis. It can serve as an accurate, non-invasive tool for identifying MASH and holds promise for risk stratification in patients with MASLD. PMID: 42957938 | PMC: PMC13719947 | DOI: 10.1186/s13244-026-02444-9
引用
- Insights into Imaging(PubMed 期刊源):MRI-based proton density fat fraction combined with adipose tissue for identifying metabolic dysfunction-associated steatohepatitis
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。